RP
Therapeutic Areas
Neurovation Labs Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Amygdala-specific AMPA receptor NAM | PTSD (with secondary indications for aggression and impulsivity) | Preclinical |
Leadership Team at Neurovation Labs
JN
Jennifer N. Perusini, Ph.D.
Chief Executive Officer
MS
Michael S. Fanselow, Ph.D.
Director of Research